Literature DB >> 28392207

Elevated clozapine levels associated with infection: A systematic review.

Scott R Clark1, Nicola S Warren2, Gajin Kim1, David Jankowiak3, Klaus Oliver Schubert4, Steve Kisely5, Tori Forrester6, Bernhard T Baune1, Dan J Siskind5.   

Abstract

Clozapine is the most effective anti-psychotic medication for treatment refractory schizophrenia. A growing number of case reports have linked infection to high clozapine levels and associated adverse outcomes. We present a systematic review of published cases to clarify the relationship between infection and elevated clozapine levels. The case reports were located through PubMed and Embase. In addition, 8 new cases from two Australian states were included. Demographics, psychiatric diagnoses and medical morbidities, medications, clinical symptoms, clozapine levels, inflammatory markers and final clinical outcome were extracted. 40 cases were identified in 23 publications that demonstrated elevated clozapine levels associated with infection. Infections were commonly respiratory in origin. Adverse events, typically sedation, were associated with raised clozapine levels during infection. In many cases the signs of infection such as fever and white blood cell count were reduced. Severe adverse effects were uncommon, with one case each of seizure, myocarditis and neutropenia. The relationship between infection, clozapine levels and adverse events is complex and multi-factorial. Monitoring of clozapine levels is essential during hospitalisation for infection and consideration should be given to gradual dose reduction to minimise dose related side effects. Crown
Copyright © 2017. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clozapine; Infection; Inflammation; Levels; Schizophrenia; Toxicity

Mesh:

Substances:

Year:  2017        PMID: 28392207     DOI: 10.1016/j.schres.2017.03.045

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  21 in total

1.  Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics.

Authors:  Jose de Leon; Emilio J Sanz; G Niklas Norén; Carlos De Las Cuevas
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

2.  A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.

Authors:  C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes
Journal:  CNS Drugs       Date:  2022-06-27       Impact factor: 6.497

3.  Consensus statement on the use of clozapine during the COVID-19 pandemic.

Authors:  Dan Siskind; William G Honer; Scott Clark; Christoph U Correll; Alkomiet Hasan; Oliver Howes; John M Kane; Deanna L Kelly; Robert Laitman; Jimmy Lee; James H MacCabe; Nick Myles; Jimmi Nielsen; Peter F Schulte; David Taylor; Helene Verdoux; Amanda Wheeler; Oliver Freudenreich
Journal:  J Psychiatry Neurosci       Date:  2020-05-01       Impact factor: 6.186

4.  Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.

Authors:  Yin Cheong Wong; Maddalena Centanni; Elizabeth C M de Lange
Journal:  J Clin Pharmacol       Date:  2019-01-24       Impact factor: 3.126

5.  Clozapine is strongly associated with the risk of pneumonia and inflammation.

Authors:  Jose de Leon; Can-Jun Ruan; Hélène Verdoux; Chuanyue Wang
Journal:  Gen Psychiatr       Date:  2020-04-16

Review 6.  [Ensuring mental health care during the SARS-CoV-2 epidemic in France: A narrative review].

Authors:  A Chevance; D Gourion; N Hoertel; P-M Llorca; P Thomas; R Bocher; M-R Moro; V Laprévote; A Benyamina; P Fossati; M Masson; E Leaune; M Leboyer; R Gaillard
Journal:  Encephale       Date:  2020-04-02       Impact factor: 1.291

Review 7.  Psychopharmacology of COVID-19.

Authors:  Melanie Bilbul; Patricia Paparone; Anna M Kim; Shruti Mutalik; Carrie L Ernst
Journal:  Psychosomatics       Date:  2020-05-18       Impact factor: 2.386

8.  Clozapine-related immunodeficiency: Implications for Parkinson's disease psychosis in the context of the COVID-19 pandemic.

Authors:  M Aubignat
Journal:  Rev Neurol (Paris)       Date:  2021-06-24       Impact factor: 2.607

Review 9.  A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.

Authors:  Jose de Leon; Can-Jun Ruan; Georgios Schoretsanitis; Carlos De Las Cuevas
Journal:  Psychother Psychosom       Date:  2020-04-14       Impact factor: 17.659

Review 10.  Ensuring mental health care during the SARS-CoV-2 epidemic in France: A narrative review.

Authors:  A Chevance; D Gourion; N Hoertel; P-M Llorca; P Thomas; R Bocher; M-R Moro; V Laprévote; A Benyamina; P Fossati; M Masson; E Leaune; M Leboyer; R Gaillard
Journal:  Encephale       Date:  2020-04-22       Impact factor: 1.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.